注射POC重建

POC Reconstitution of Injectable Drugs

出版日期: 2022年12月31日 | 出版商:

Greystone Research Associates | 英文 100 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

生物製品固有的不稳定性是一个直接影响药物输送领域的限制。治疗性蛋白质必须在特殊条件下储存或配製以保持从製造到配製的效力。液体蛋白药物在配药前应冷藏。或者，可以将蛋白质配製成粉末（冻干），但必须在註射前重新配製。

本报告探讨了注射剂 POC 中的重构，并概述了药物重构，包括生物製剂趋势、竞争格局和市场进入者概况。

内容

执行摘要
注射剂的 PoC 重构
药物重组市场动态
重组 - 生物製药生活事实
可注射药物生态系统
设备设计的演变
组合因子
产品专用设备开发
推动特殊注射设备需求的因素
慢性病和自我管理
生物製剂的增长
处方药
患者人口统计数据的变化
安全与合规
设备设计和创新
竞争格局
技术市场驱动力
用于 POC 重建的集成设备
双腔墨盒
双腔进样器
双腔注射器
可穿戴式自动侦察系统
设备评估
产品专用设备
特殊设备
OEM 设备
双腔安全注射器
治疗部分 - 数据和预测
激素替代
感染
代谢状态
骨质疏鬆症
神经学
肿瘤学
再生医学
其他疗法部分
市场因素
设备产品策略
设备经济学
产品品牌
直接面向消费者的销售
管理式医疗的趋势
公司简介

简介目录

Product Code: RJD929K

“POC Reconstitution of Injectable Drugs ” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for reconstitution systems for injectable drug products . Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Engineered Injectables that Address Chronic Conditions

The inherent instability of biological drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed. Alternatively, proteins can be formulated as powders (lyophilization) and must be reconstituted prior to injection. Historically, this was accomplished by including a disposable syringe and diluent vial for manual reconstitution. As the number of drugs developed for self-administration has grown, devices that integrate a reconstitution step with the injection step have gained traction. As biological drugs continue to grow in terms of therapeutics and total prescriptions, the impact of specialty devices will increase.

What You Will Learn:

What is the impact of lyophilized injectable drugs on today's therapeutic market, how are they packaged, and who markets them?

Who are the suppliers of integrated reconstitution devices, and what is their market impact?

What are the major factors driving the demand for integrated devices for injectable drug reconstitution?

What is the relative impact of integrated reconstitution systems to OEM or standalone reconstitution devices and how will this change by the end of the decade?

What are the essential design factors, material selection issues, technologies and market development issues for drug reconstitution systems and devices?

What is the role of integrated drug reconstitution systems on drug life cycle management?

What are the significant economic, technology, and regulatory factors affecting the market for injectable drugs and reconstitution systems in particular?